Lee and AstraZeneca: India's next David and Goliath compulsory license fight?
This article was originally published in Scrip
Executive Summary
A 40% chance for success and mere "publicity stunt" are some of the sharp early reactions to the surprise compulsory license (CL) application for AstraZeneca's saxagliptin by the Hyderabad-based Lee Pharma, though the less know firm appears confident that its arguments hold water.